Yttrium-90 radioembolization using TheraSphere in the management of primary and secondary liver tumors.
Locoregional therapies, such as transarterial chemoembolization, radioembolization and thermal ablation (e.g., radiofrequency ablation) are establishing their roles in the management of liver malignancies. With yYttrium-90 radioembolization therapy (90Y) radionuclide labeled microspheres are injected into the tumor feeding artery. This allows the delivery of a high radioactive dose to the tumor with minimal toxicity to normal tissues. 90Y has demonstrated to be safe and effective in the management of liver tumors. Authors present a review of the literature available for the use of TheraSphere for radioembolization in the management of liver tumors.
Riaz
A
A
Department of Radiology, Northwestern University, Chicago, IL 60611, USA.
Lewandowski
R J
RJ
Kulik
L
L
Salem
R
R
D006528:Carcinoma, Hepatocellular / Q000532:radiotherapy* / Q000556:secondary*; D006801:Humans; D008113:Liver Neoplasms / Q000532:radiotherapy*; D011868:Radioisotopes / Q000008:administration & dosage*; D019275:Radiopharmaceuticals / Q000008:administration & dosage*; D011879:Radiotherapy Dosage; D015021:Yttrium Radioisotopes / Q000008:administration & dosage*
D011868:Radioisotopes; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes